Seres Therapeutics Inc (NASDAQ:MCRB) has been assigned a $20.00 price objective by Canaccord Genuity in a report released on Thursday, May 4th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s price objective would suggest a potential upside of 105.13% from the stock’s current price.
MCRB has been the topic of a number of other reports. Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Seres Therapeutics in a research note on Tuesday, March 21st. FBR & Co lowered their price target on shares of Seres Therapeutics from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, February 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $23.20.
Seres Therapeutics (NASDAQ:MCRB) traded down 1.02% on Thursday, reaching $9.75. 134,517 shares of the company’s stock were exchanged. The company’s market cap is $393.80 million. Seres Therapeutics has a 12-month low of $8.05 and a 12-month high of $35.98. The firm has a 50 day moving average of $10.18 and a 200-day moving average of $10.26.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. The company had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $3 million. During the same period in the previous year, the firm posted ($0.50) earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Equities analysts expect that Seres Therapeutics will post ($2.63) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics Inc (MCRB) Given a $20.00 Price Target at Canaccord Genuity” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/05/20/canaccord-genuity-analysts-give-seres-therapeutics-inc-mcrb-a-20-00-price-target-updated.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock worth $17,645,000 after buying an additional 103,456 shares during the last quarter. Capital World Investors increased its stake in shares of Seres Therapeutics by 279.3% in the third quarter. Capital World Investors now owns 1,337,000 shares of the biotechnology company’s stock worth $16,432,000 after buying an additional 984,500 shares in the last quarter. Artal Group S.A. increased its stake in shares of Seres Therapeutics by 40.0% in the fourth quarter. Artal Group S.A. now owns 700,000 shares of the biotechnology company’s stock worth $6,930,000 after buying an additional 200,000 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of Seres Therapeutics during the fourth quarter worth $4,871,000. Finally, Renaissance Technologies LLC boosted its stake in Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock worth $3,963,000 after buying an additional 103,800 shares during the last quarter. Institutional investors own 77.62% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.